A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Clinical trial NCT06777316 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06777316
Sponsor: Cogent Biosciences, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Intrahepatic Cholangiocarcinoma (Icc)Cholangiocarcinoma Other Solid Tumors, Adult FGFR2 Gene Fusion/Rearrangement FGFR2 Gene Amplification FGFR2 Gene Short Variants FGFR3 Gene Fusion/Rearrangement FGFR3 Gene Amplification FGFR3 Gene Short Variants FGFR2 Genetic Alterations FGFR3 Genetic Alterations Advanced Solid Tumors

Start date: 2025-01-22
Primary completion: 2027-03-01
Enrollment: 110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.